FDA Approval Sought for Female Sexual Disorder Drug

Share this article:

Flibanserin, a non-hormonal drug for the treatment of hypoactive sexual desire disorder (HSDD) in post-menopausal women, has been resubmitted for a New Drug Application, the drug's maker, Sprout Pharmaceuticals, of Raleigh, NC, announced.

Flibanserin demonstrated significant improvements in sexual events in a phase 3 randomized, placebo-controlled trial that included 1,100 premenopausal women with HSDD. The drug was well-tolerated in patients during the 24-week period.

“The consistency of flibanserin's statistically significant effect on satisfying sexual events and desire, while decreasing the distress of women experiencing HSDD, is very encouraging,” said Sheryl Kingsberg, PhD, of the Case Western Reserve University School of Medicine in Cleveland.

If it is approved, flibanserin will be the first biopharmaceutical option for women with sexual dysfunction.

In June 2010, the FDA voted against recommending and approving the drug—which was then being developed by Boehringer Ingelheim—for lack of compelling evidence.

Sprout expects FDA action before the end of 2013.

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Reproductive Medicine

More in Reproductive Medicine

Fertility Treatment Less Effective in Black Women

Fertility Treatment Less Effective in Black Women

Success rates for in vitro fertilization seen in black women are half those of white women.

Caffeine Hinders While Alcohol Aids Infertility Therapy in Men

Caffeine Hinders While Alcohol Aids Infertility Therapy in ...

Researchers suggest male beverage consumption of caffeine and alcohol affects in vitro fertilization results.

High Alcohol Intake Harms Sperm Quality

High Alcohol Intake Harms Sperm Quality

Drinking alcohol confers higher rate of sexually transmitted infections and a drop in sperm quality.